ARTICLE | Clinical News
IMGN779: Phase I started
April 25, 2016 7:00 AM UTC
ImmunoGen Inc. (NASDAQ:IMGN), Waltham, Mass. Product: IMGN779 Business: Cancer Molecular target: CD33 Description: Antibody-drug conjugate (ADC) consisting of Z4681A, a humanized anti-CD33 antibody,...